Symbols

CALT(Delisted)

Calliditas·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 1

Hanging Man

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CALT

Calliditas Therapeutics Ab

A commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications

Industry

Established Date

02/20/2004

Listing Date

06/05/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

217

Fiscal Year Ends

12-31

Website

www.calliditas.se

Security Type

Depository Receipts (Ordinary Shares)

Office address

Kungsbron 1, D5, SE-111 22, Stockholm, Sweden

Business

Introduction

Founded on February 20, 2004, Calliditas Therapeutics AB is a clinical-stage biopharmaceutical company dedicated to identifying, developing and commercializing new therapies for orphan indications, with an initial focus on kidney and liver diseases with unmet medical needs, the lead drug candidate, Nefecon, is a novel proprietary oral formulation of budesonide, an established, An effective topical immunosuppressant for the treatment of autoimmune kidney disease IgA nephropathy or IgAN, which is in high medical demand and there are no approved treatments. IgAN is a progressive chronic disease that over time leads to deterioration of kidney function in patients, many of whom are at risk of eventually developing end-stage renal disease or ESRD, requiring dialysis or kidney transplantation. Nefecon is currently the only disease-modifying drug candidate in IgAN development.

Company Financials

EPS

CALT has released its 2023 Q4 earnings. EPS was reported at -0.06, versus the expected -0.07, beating expectations. The chart below visualizes how CALT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CALT has released its 2024 Q2 earnings report, with revenue of 52.81M, reflecting a YoY change of 111.38%, and net profit of -4.48M, showing a YoY change of 47.47%. The Sankey diagram below clearly presents CALT's revenue sources and cost distribution.